LJ-1888, a selective antagonist for the A3 adenosine receptor, ameliorates the development of atherosclerosis and hypercholesterolemia in apolipoprotein E knock-out mice.
This study assessed whether LJ-1888, a selective antagonist for A3 AR, can inhibit the development of atherosclerosis in apolipoprotein E knock-out (ApoE-/-) mice who are fed a western diet. Plaque formation was significantly lower in ApoE-/- mice administered LJ-1888 than in mice not administered LJ-1888, without any associated liver damage. LJ-1888 treatment of ApoE-/- mice prevented western diet-induced hypercholesterolemia by markedly reducing low-density lipoprotein cholesterol levels and significantly increasing high-density lipoprotein cholesterol concentrations. Reduced hypercholesterolemia in ApoE-/- mice administered LJ-1888 was associated with the enhanced expression of genes involved in bile acid biosynthesis. These findings indicate that LJ-1888, a selective antagonist for A3 AR, may be a novel candidate for the treatment of atherosclerosis and hypercholesterolemia.
PMID: 29936931 [PubMed - as supplied by publisher]
Source: BMB Reports - Category: Biochemistry Authors: Park JG, Jeong SJ, Yu J, Kim G, Jeong LS, Oh GT Tags: BMB Rep Source Type: research
More News: Arthritis | Asthma | Bile | Biochemistry | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cholesterol | Diets | Genetics | Heart | Liver | Nutrition | Rheumatoid Arthritis | Rheumatology | Study | Urology & Nephrology